Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University: related news

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

CAMBRIDGE, Mass. - (Business Wire) Elixir Pharmaceuticals, Inc., today announced the Company has entered an exclusive license agreement with Boston University to key intellectual property covering discoveries regarding the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes. SIRT1 is the human equivalent of Sir2, a gene identified in yeast that has been recognized to play a key role in the control of lifespan, metabolism, resistance to stress and other cellular regulatory pathways. The agreement with Boston University encompasses therapeutic applications for SIRT1 modulators in metabolic diseases, including obesity and diabetes, as well as therapeutic modulation of SIRT1 for anti-angiogenic activity to treat cancer.

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

Elixir Pharmaceuticals Announces Exclusive Sirtuin Intellectual Property License Agreement with Boston University

DUSA Announces Patent Licensing Agreement

DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

WILMINGTON (Marketwire) - DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM:DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license. As part of the agreement, DUSA will receive a share of the net revenues River's Edge generates.

DUSA Announces Patent Licensing Agreement

WILMINGTON, MASSACHUSETTS -- 08/14/08 -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

WILMINGTON, MASSACHUSETTS--(Marketwire) - Aug. 14, 2008 - DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM:DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

WILMINGTON, MASSACHUSETTS--(Marketwire - Aug. 14, 2008) - DUSA Pharmaceuticals, Inc.(R) (NASDAQ GM:DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

DUSA Announces Patent Licensing Agreement

WILMINGTON, MASSACHUSETTS--(MARKET WIRE)--Aug 14, 2008 -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) today announced that it has entered into a non-exclusive patent license agreement granting River's Edge Pharmaceuticals, LLC rights for a vitamin-mineral product (nicotinamide, zinc, copper and folic acid) in the prescription market. DUSA is taking this action in light of the entry of generic products in this market and DUSA's need to enforce its intellectual property rights while trying to avoid litigation. DUSA, which previously sold its patented product in this market, now plans to sell its product under the dietary supplement rules as a result of discussions with the Food and Drug Administration. The one-year agreement is subject to an extension under certain terms and conditions and does not include a trademark license.

MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides

MDRNA, Inc. (Nasdaq: MRNA) announced today that it has signed an exclusive license agreement to intellectual property from the University of Michigan covering cationic peptides for enhanced delivery of nucleic acids. Terms of the agreement were not disclosed.

Alnylam Grants New InterfeRx Intellectual Property License to Calando for Development and Commercialization of RNAi Therapeutics

CAMBRIDGE, Mass. & PASADENA, Calif.--(BUSINESS WIRE)--Jul 21, 2008 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has granted Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR), a new target-specific InterfeRx(TM) license to discover, develop, and commercialize a synthetic siRNA directed toward an undisclosed cancer gene target. The new non-exclusive, gene-specific license agreement includes an Alnylam right of first negotiation to opt-in for co-development and co-commercialization of the RNAi therapeutic product in the U.S. market. Detailed financial terms were not disclosed, but include upfront, and milestone payments, and royalties on sales of any products covered by the licensing agreement.

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

MONTVALE, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

Barr Announces Agreements to Settle Mirapex(R) and Aggrenox(R) Patent Challenges

MONTVALE, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL - News) announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex® product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox® product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox®.

Barr Announces Agreements to Settle Mirapex and Aggrenox Patent Challenges

MONTVALE, N.J., August 12, 2008 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. announced today that its Barr Laboratories subsidiary has signed a Settlement Agreement and a License Agreement with Boehringer Ingelheim to resolve the patent litigation involving Boehringer Ingelheim's Mirapex(R) product. Separately, Barr Laboratories entered into a Settlement Agreement and a Supply Agreement to resolve the patent litigation regarding Boehringer Ingelheim's Aggrenox(R) product and Duramed Pharmaceuticals, a subsidiary of Barr Pharmaceuticals, entered into a Co-Promotion Agreement with Boehringer Ingelheim relating to Aggrenox(R).

Alnylam Obtains Intellectual Property For RNA Activation, Turning Genes On Instead of Off

Alnylam Pharmaceuticals, the Cambridge, MA-based developer of drugs that work by inhibiting production of certain proteins, said today it has obtained key intellectual property for technology to do the opposite. The company (NASDAQ: ALNY) completed exclusive license agreements with the University of Texas Southwestern Medical Center, the University of California, San Francisco, and the Salk Institute for Biological Studies. Many human diseases are caused by low production of certain proteins, and the new technology, dubbed RNAa, could help by activating the genes that encode those proteins, said Alnylam CEO John Maraganore in a statement.

China Biggest Threat to Korean Intellectual Property

The most serious threat to the intellectual property of Korean businesses comes from China, especially in the electric and electronics fields, a poll suggests. The survey was conducted by Gallup Korea for the Korean Intellectual Property Office on the overseas intellectual property cases of 1,202 domestic firms. Some 65 percent of all cases happened in China, and 12 percent each in Taiwan and in the United States.

Akerman's Jill Riola Achieves Florida Bar Board Certification in Intellectual Property Law

ORLANDO, Fla., Aug. 18 /PRNewswire/ -- Akerman Senterfitt Shareholder Jill Sarnoff Riola has received Board Certification in Intellectual Property Law from The Florida Bar. In 2007, the Florida Supreme Court officially recognized intellectual property law as one of only 22 board certification areas available in Florida. Board Certification is the highest level of recognition by The Florida Bar of competency and experience, and identifies Ms. Riola as having special knowledge, skills and proficiency in Intellectual Property law, distinguishing her as a specialist in this practice area.

Akerman's Jill Riola Achieves Florida Bar Board Certification in Intellectual Property Law

ORLANDO, Fla., Aug. 18 /PRNewswire/ -- Akerman Senterfitt Shareholder Jill Sarnoff Riola has received Board Certification in Intellectual Property Law from The Florida Bar. In 2007, the Florida Supreme Court officially recognized intellectual property law as one of only 22 board certification areas available in Florida. Board Certification is the highest level of recognition by The Florida Bar of competency and experience, and identifies Ms. Riola as having special knowledge, skills and proficiency in Intellectual Property law, distinguishing her as a specialist in this practice area.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Search took 0.35 seconds.